Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 6, 2026, reports the closing of a material definitive agreement and a concurrent debt financing transaction. Aspire Biopharma Holdings, Inc. (the "Company") is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transactions
- Debt Financing: The Company issued convertible promissory notes with an aggregate principal amount of $3,750,000.
- Proceeds: The aggregate purchase price received was $3,000,000, reflecting a 20% original issue discount.
- Conversion Terms: Notes are convertible into common stock at a price of $8.00 per share.
- Transaction Costs: RBW Capital Partners LLC received a placement agency fee of 8% of the purchase price and non-accountable expenses of 1%.
- Acquisition Closing: The Company closed the purchase of equity interests and assets from FireFish TopCo, LLC (the "Seller") pursuant to a Purchase Agreement originally entered into in June 2026.
Material Changes and Transaction Details
The primary material change is the consummation of the acquisition of the "Transferred Entities" and related assets from FireFish TopCo, LLC. The closing occurred automatically upon the Company's payment of the Closing Purchase Price, which was contingent on the receipt of funds from the new debt financing. While the financing was not a formal condition to the closing under the Purchase Agreement, the Seller entered into an Escrow and Closing Agreement as an accommodation to allow the Company time to secure funds.
Outlook, Risks, and Management Commentary
Management intends to use the $3,000,000 in proceeds to provide additional working capital and to pursue future growth opportunities. The filing notes that the Seller retained the right to terminate the Purchase Agreement if the closing did not occur promptly after July 31, 2026, though the closing was successfully effected on August 6, 2026. The notes and conversion shares were sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the exact amount of the "Closing Purchase Price" for the FireFish TopCo, LLC acquisition, as the specific dollar value is not stated in this filing (referenced in the June 8-K).
- Review the full text of the Convertible Promissory Note (Exhibit 10.4) for maturity dates, interest rates, and specific conversion mechanics.
- Confirm the number of shares of common stock that will be issued upon full conversion of the $3,750,000 principal at the $8.00 conversion price.
- Assess the impact of the 20% original issue discount on the Company's effective cost of capital.
- Examine the June 12, 2026 Form 8-K for detailed terms of the Purchase Agreement with FireFish TopCo, LLC.